Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline PLC Add to portfolio

LON100:GSK, Apr 26, 04:25 UTC

Latest LON100:GSK News

Filter your feed

Apply Filter

Wednesday, April 24


News

GlaxoSmithKline (LON:GSK) share price: what to expect from its Q1 results

GSK GSK

CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. At the end of what was a very successful 2018, GSK announced it would form a new world-leading consumer healthcare joint venture (JV) with rival Pfizer in a move that will see its combined businesses generate sales of around £9.8 billion. Investors will welcome an update on the JV, which brings together two highly complementary portfolios of consumer health brands, including GSK’s Sensodyne, Voltaren, and Panadol, alongside Pfizer’s Advil, Centrum and Caltrate. Investors will have their eye on what GSK intends to pay in dividends to shareholders for 2019, with the JV allowing them to confirm an 80p a share payout, which its management intends to maintain.

Read Full Details

Story Sources

ig.com ig.com
Topics:
  • Business
  • Financial

Monday, April 22


News

Global Lennox-Gastaut Syndrome Treatment Market 2019-2023 - Key Players are Eisai, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson Services, and Supernus Pharmaceuticals - ResearchAndMarkets.com

GSK GSK

Global Lennox-Gastaut Syndrome Treatment Market 2019-2023 - Key Players are Eisai, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson Services, and Supernus Pharmaceuticals - ResearchAndMarkets.com. The growing prevalence of infectious diseases including encephalitis and meningitis will further increase the risk of the development of LGS. As a result, a rising number of patients with these risk factors will drive the LGS treatment market growth during the forecast period. The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read Full Details

Topics:
  • Business
  • Health

Wednesday, April 17


News

Bio-pharma Market Competitive Analysis to 2024: Pfizer, Roche, Johnson & Johnson, Sanofi, Amgen, AbbVie, Merck, Biogen, Bayer, Eli Lilly and Company, Novartis, GSK

BAYN PFE +7 more BAYN PFE MRK SAN LLY GSK ABBV BIIB AMGN

Bio-pharma Market Competitive Analysis to 2024: Pfizer, Roche, Johnson & Johnson, Sanofi, Amgen, AbbVie, Merck, Biogen, Bayer, Eli Lilly and Company, Novartis, GSK. The Bio-pharma Market is increasing the forecast years of 2018-2024 and pulling the Chemicals and Materials industry with it. The numerical data is backed up by statistical tools such as SWOT analysis, Porter’s Five Forces Analysis and else. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. Some Of the Key Players in Bio-pharma Market Include:.

Read Full Details

Topics:
  • Business
  • Health
  • Science
  • Financial

Tuesday, April 16


News

AI Test Pinpoints More Cancers Targeted by Astra, Glaxo Drugs

GSK

Using artificial intelligence to pinpoint tumour cells with reduced ability to repair their own DNA can help identify tens of thousands of patients who would benefit from treatment with drugs from AstraZeneca and GlaxoSmithKline, researchers said. Analysing genetic tests with a machine-learning algorithm helps target cancers that are vulnerable to treatment with drugs called PARP inhibitors, according to a study from scientists at Harvard Medical School in Boston and the UK's University of Cambridge. Oncologists often determine whether patients will receive PARP inhibitors like Astra's Lynparza or Glaxo's Zejula by testing for flaws in certain gene mutations that block cells from fixing their own DNA using a specific mechanism. Yet many tumours without those mutations may also have the same genetic repair deficit, but are harder to find because there's no specific gene test. The algorithm finds patterns in tumours that show whether they have a deficiency in homologous DNA repair, which makes them susceptible to treatment by PARP inhibitors, researchers led by Harvard research fellow Doga Gulhan said Monday in the journal Nature Genetics.

Read Full Details

Topics:
  • Health
  • Technology
  • Science

Friday, April 12


News

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

MRK AZN +2 more MRK AZN GSK AZN

The regulatory submission was based on the global GEMINI 1 & 2 studies, 48-week data from which demonstrated that the dolutegravir and lamivudine regimen was non-inferior to the standard three-drug regimen. AstraZenec/Merck’s Lynparza Gets Approval for Breast Cancer in EU: AstraZeneca and Merck gained approval in the EU for their PARP inhibitor, Lynparza (olaparib) in a new patient population — germline BRCA-mutated HER2-negative advanced breast cancer previously treated with chemotherapy. It is approved for first-line treatment of patients with stage III or metastatic non-small cell lung cancer whose tumors expressed PD-L1 in at least 1% of tumor cells, with no EGFR or ALK genomic tumor aberrations. J&J Presents New Data on Symtuza: At a medical meeting, J&J JNJ presented new 48-week data from the DIAMOND study, which evaluated the benefits of rapid initiation of its once-daily single-tablet HIV regimen Symtuza. (See the last pharma stock roundup here: Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU). What's Next in the Pharma World?

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

GlaxoSmithKline (GSK) Given a GBX 1,600 Price Target by Credit Suisse Group Analysts

BAS GSK +1 more BAS GSK GSK

Credit Suisse Group’s price objective indicates a potential upside of 2.05% from the company’s previous close. Bank of America set a GBX 1,635 ($21.36) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Friday, December 14th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. GlaxoSmithKline has a 52 week low of GBX 1,395.80 ($18.24) and a 52 week high of GBX 1,648.80 ($21.54).

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, April 09


News

Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients

GSK

Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients. GlaxoSmithKline plc’s GSK HIV subsidiary, ViiV Healthcare announced that the FDA has granted approval to a new once-daily, single-tablet two-drug regimen (2DR), Dovato for the treatment of newly-diagnosed adults with HIV-1 infection. Juluca was approved in the United States in late 2017 and in the EU in mid-2018 for HIV patients that have received prior treatment. So far this year, Glaxo’s shares have outperformed the industry, rising 9.1% compared with 3.6% increase for the industry. ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms (two-drug regimens), new modalities (long-acting injectables) and new mechanisms of actions (including maturation inhibitors and broadly neutralising antibodies).

Read Full Details

Topics:
  • Business
  • Health

Monday, April 08


News

GSK wins U.S. nod for two-drug HIV combination

GSK

GSK wins U.S. nod for two-drug HIV combination. April 8 (Reuters) - GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc. GSK showed in drug trials last year that the once-a-day Dovato pill was as good as a standard three-drug cocktail in suppressing the virus that causes AIDS and also in terms of tolerability. GSK's HIV drugs division ViiV, in which Pfizer Inc and Shionogi & Co Ltd have small stakes, will use the lower drug burden as its main selling point to patients and physicians, while hoping that longer-term studies will yield hard evidence of fewer side effects over time. As HIV positive patients grow older thanks to highly effective treatment, the focus shifts to long-term side effects as nearly half of all HIV patients in the profitable markets of North America and Europe are now over 50.

Read Full Details

Topics:
  • Business
  • Health
News

U.S. FDA approves GSK's two-drug HIV treatment

GSK

U.S. FDA approves GSK's two-drug HIV treatment. ReutersApril 8, 2019, 7:46 PM GMT. April 8 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved GlaxoSmithKline Plc's two-drug HIV treatment. The approval was granted to GSK's majority-owned HIV unit ViiV Healthcare, the FDA said. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta). What to read next.

Read Full Details

Topics:
  • Business
  • Health
  • Technology

Thursday, April 04


News

U.S., China key to GSK's consumer venture with Pfizer

PFE GSK

The venture, to be 68 percent owned by GSK, will become a stand-alone company within three years of closing the deal, and McNamara will lead it. "The U.S. and China are really two of the key value drivers of the deal because it's where Pfizer has critical mass and a significant amount of their key brands," he said in an interview, noting the new entity will be the No.1 player in the United States and No.2 in China. The consumer health sector, which spans vitamins, non-prescription medicines and other drug store purchases, is buoyed by ageing populations, a growing interest in health, wellness and self-care, and growing middle classes. The new, yet-to-be-named company will have annual sales of 9.8 billion pounds ($12.9 billion) and more than 7 percent of the global consumer health market, with brands also including Centrum vitamins and Sensodyne toothpaste.

Read Full Details

Topics:
  • Business
  • Health
  • Financial